secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2026-05-12T11:14:36+00:00
Accession:  0001628280-26-033874
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas and Pfizer out-license VEPPANU to Rigel for $85M upfront; potential $320M milestones
--------------------------------------------------------------------------------

- Rigel pays $70M upfront plus up to $15M upon completion of transition activities; split evenly with Pfizer.
- Arvinas and Pfizer eligible for up to $320M in development, regulatory, and commercial milestones.
- Tiered royalties on worldwide net sales in the mid-teens to mid-20s, also split evenly.
- Rigel contributes up to $40M toward ongoing development; Arvinas/Pfizer continue current activities.
- Closing subject to HSR waiting period; NCCN added vepdegestrant as Category 2A on May 8, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000162828026033874/0001628280-26-033874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000162828026033874/arvn-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-033874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer